secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cyclo Therapeutics, Inc. (—)
CIK:        0000922247
Form:       8-K
Filed at:   2023-11-30T23:59:59+00:00
Accession:  0001437749-23-033256
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cyclo Therapeutics receives Nasdaq delisting notice for low equity; expects cure via AMTI merger
--------------------------------------------------------------------------------

- Stockholders' equity of $1,052,670 as of Sep 30, 2023, below Nasdaq's $2.5M minimum.
- Nasdaq scheduled trading suspension for Dec 6, 2023 unless appeal; company will request hearing by Dec 4.
- Company expects to meet equity requirement by year-end using cash from pending merger with Applied Molecular Transport (AMTI).
- Merger agreement signed Sep 21, 2023; S-4 declared effective Nov 21, proxy mailed Nov 27.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/922247/000143774923033256/0001437749-23-033256-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/922247/000143774923033256/ctdh20231129_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-033256

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer